Aldeyra Therapeutics, J&J collaborate to treat Systemic Inflammatory Diseases
01 March 2018 | News
Aldeyra plans to collaborate with Janssen on the development of novel drugs designed to sequester pro-inflammatory aldehyde mediators
Aldeyra Therapeutics, Inc. a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases.
The company announced that it has entered into a collaborative research agreement with Janssen Research & Development, LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Aldeyra plans to collaborate with Janssen on the development of novel drugs designed to sequester pro-inflammatory aldehyde mediators, a new class of therapeutic targets.
Aldeyra's aldehyde sequestration platform represents a novel therapeutic class, led by reproxalap, a first-in-class drug candidate that has demonstrated anti-inflammatory activity in four Phase 2 clinical trials.
The agreement is intended to advance the development of existing analogs of reproxalap for the treatment of systemic inflammatory diseases.
